[HTML][HTML] Sulfasalazine

J Choi, P Patel, A Fenando - StatPearls [Internet], 2024 - ncbi.nlm.nih.gov
Objectives: Describe the mechanism of action of sulfasalazine. Identify the adverse effects
and contraindications of sulfasalazine. Determine appropriate monitoring steps and toxicity …

[PDF][PDF] Clinical and pharmacological aspects of sulfasalazine

PAM van Hees - 1979 - repository.ubn.ru.nl
clinical and pharmacological aspects of sulfasalazine Page 1 clinical and pharmacological
aspects of sulfasalazine pam van hees Page 2 Page 3 clinical and pharmacological aspects …

Sulfasalazine: a review of its use in the management of rheumatoid arthritis

GL Plosker, KF Croom - Drugs, 2005 - Springer
Summary Abstract Sulfasalazine (salazosulfapyridine)[Azulfidine®, Salazopyrin®] is a well
established disease-modifying antirheumatic drug (DMARD) used in the treatment of …

Reversal of refractory sulfasalazine-related renal failure after treatment with corticosteroids

P Alivanis, G Aperis, F Lambrianou, A Zervos… - Clinical …, 2010 - Elsevier
Background: Sulfasalazine is a combination of sulfapyridine and 5-aminosalicylic acid and
is used as a first-line treatment in inflammatory bowel disease. Objective: We describe a …

Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis

CP Rains, S Noble, D Faulds - Drugs, 1995 - Springer
Synopsis Sulfasalazine was first used for rheumatic polyarthritis in the 1940s and in the past
2 decades has become firmly established as a disease-modifying antirheumatic drug …

The risk of sulfasalazine‐and mesalazine‐associated blood disorders

H Jick, MW Myers, AD Dean - Pharmacotherapy: The Journal …, 1995 - Wiley Online Library
Sulfasalazine (SASP) has often been reported to cause serious blood disorders, particularly
agranulocytosis; however, little quantitative information is available to estimate the risk or to …

Sulfasalazine for treating rheumatoid arthritis

ME Suarez‐Almazor, E Belseck, B Shea… - Cochrane Database …, 1996 - cochranelibrary.com
Background Sulfasalazine has become a common second line drug (DMARD) for the
treatment of rheumatoid arthritis (RA). Objectives To estimate the short‐term efficacy and …

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

A Abhishek, M Grainge, T Card, HC Williams… - RMD open, 2024 - rmdopen.bmj.com
Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is
uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring …

The history of the use of sulphasalazine in rheumatology

RS Amos - Rheumatology, 1995 - academic.oup.com
Sulphasalazine was initially used more than 50 yr ago to treat inflammatory arthritis but fell
into disuse, only to be revived 25 yr ago for rheumatoid arthritis. Since then its place as a …

[HTML][HTML] Sulfasalazine-induced crystalluria causing severe acute kidney injury

M Durando, H Tiu, JS Kim - American Journal of Kidney Diseases, 2017 - Elsevier
Sulfasalazine is an anti-inflammatory agent commonly used in the treatment of autoimmune
conditions such as inflammatory bowel disease and rheumatoid arthritis. Sulfasalazine is …